Related Experiment Video
Updated: May 19, 2026

Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
Novel targets for platelet inhibition
Kathleen Freson1, Chris Van Geet
1Center for Molecular and Vascular Biology, University of Leuven, Herestraat 49, 3000, Leuven, Belgium. Kathleen.Freson@med.kuleuven.be
Dual antiplatelet therapy is standard for atherothrombotic disease but has limitations. Research into novel antiplatelet targets is advancing due to the need for improved safety and efficacy in preventing cardiovascular events.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Genetics
Background:
- Atherothrombosis is a major cause of cardiovascular diseases like coronary artery disease and stroke.
- Antiplatelet drugs are crucial for preventing atherothrombotic events.
- Current dual antiplatelet therapy (aspirin plus clopidogrel) has limitations, including bleeding risks.
Purpose of the Study:
- To explore the investigation of novel antiplatelet targets.
- To address the limitations of current antiplatelet therapies.
Main Methods:
- Review of research into novel antiplatelet targets.
- Identification of target discovery methods including genomics, proteomics, and genetic analysis.
Main Results:
- Significant research efforts have focused on identifying new antiplatelet targets.
- Multiple approaches, including large-scale omics studies and genetic analysis, are employed.
Conclusions:
- Novel antiplatelet targets are being actively investigated to improve upon existing therapies.
- Advances in genomics and proteomics are driving the discovery of new therapeutic strategies for atherothrombosis.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Structure and Function of Platelets
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins

